CRP 1059 G/C and 1846G/A polymorphisms and cancer risk: A meta-analysis of 26,634 subjects - 04/10/14
pages | 6 |
Iconographies | 1 |
Vidéos | 0 |
Autres | 0 |
Summary |
Background and objective |
Previous studies have shown that C-reactive protein (CRP) 1059G/C and 1846G/A polymorphisms may play a role in cancer risk. However, the results from the published studies are conflicting. To derive a more precise estimation of the relationship between CRP 1059G/C and 1846G/A polymorphisms and cancer risk, we conducted a meta-analysis of 21 studies involving a total of 26,634 subjects.
Methods |
Odds ratios (ORs) and 95% confidence intervals (CIs) were used to assess the strength of the association.
Results |
No significant association was found between CRP 1846G/A polymorphism and cancer risk. However, a significant association was found between CRP 1059G/C polymorphism and cancer risk (CC vs CG+GG: OR=3.60, 95% CI=1.63–7.92, PH=0.67; CC vs GG: OR=3.53, 95% CI=1.60–7.77, PH=0.69). In the subgroup analysis by ethnicity, a significant association was found for the CRP 1846G/A polymorphism among mixed population. Interestingly, when stratifying by cancer type, marginally increased risks were observed for CRP 1846G/A polymorphism in colorectal cancer (AA vs AG+GG: OR=1.17, 95% CI=1.00–1.36, PH=0.27) and significantly decreased risks were found for CRP 1846G/A polymorphism in breast cancer (AA vs GG: OR=0.73, 95% CI=0.56–0.95, PH=0.93; A vs G: OR=0.88, 95% CI=0.79–0.99, PH=0.54). For 1059G/C polymorphism, a significant association was found in colorectal cancer.
Conclusion |
This meta-analysis showed the evidence that CRP 1059G/C and 1846G/A polymorphisms were risk factors for the development of colorectal cancer, and CRP 1846G/A polymorphism is also a protective factor for decreasing breast cancer.
Le texte complet de cet article est disponible en PDF.Plan
Vol 38 - N° 5
P. 607-612 - octobre 2014 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?